These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 26743812)
21. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial. McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067 [TBL] [Abstract][Full Text] [Related]
22. Caseworker-assigned discharge plans to prevent hospital readmission for acute exacerbations in children with chronic respiratory illness. Hall KK; Petsky HL; Chang AB; O'Grady KF Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012315. PubMed ID: 30387126 [TBL] [Abstract][Full Text] [Related]
23. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG; Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288 [TBL] [Abstract][Full Text] [Related]
25. A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial. Gunatilake S; Brims FJ; Fogg C; Lawrie I; Maskell N; Forbes K; Rahman N; Morris S; Ogollah R; Gerry S; Peake M; Darlison L; Chauhan AJ Trials; 2014 Sep; 15():367. PubMed ID: 25238873 [TBL] [Abstract][Full Text] [Related]
26. The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given 'as needed' in mild asthma: study protocols for two randomised controlled trials. O'Byrne PM; FitzGerald JM; Zhong N; Bateman E; Barnes PJ; Keen C; Almqvist G; Pemberton K; Jorup C; Ivanov S; Reddel HK Trials; 2017 Jan; 18(1):12. PubMed ID: 28069068 [TBL] [Abstract][Full Text] [Related]
27. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial. Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494 [TBL] [Abstract][Full Text] [Related]
28. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Gibson PG; Yang IA; Upham JW; Reynolds PN; Hodge S; James AL; Jenkins C; Peters MJ; Marks GB; Baraket M; Powell H; Taylor SL; Leong LEX; Rogers GB; Simpson JL Lancet; 2017 Aug; 390(10095):659-668. PubMed ID: 28687413 [TBL] [Abstract][Full Text] [Related]
29. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Castro M; Zangrilli J; Wechsler ME; Bateman ED; Brusselle GG; Bardin P; Murphy K; Maspero JF; O'Brien C; Korn S Lancet Respir Med; 2015 May; 3(5):355-66. PubMed ID: 25736990 [TBL] [Abstract][Full Text] [Related]
30. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936 [TBL] [Abstract][Full Text] [Related]
31. The feasibility of early pulmonary rehabilitation and activity after COPD exacerbations: external pilot randomised controlled trial, qualitative case study and exploratory economic evaluation. Cox M; O'Connor C; Biggs K; Hind D; Bortolami O; Franklin M; Collins B; Walters S; Wailoo A; Channell J; Albert P; Freeman U; Bourke S; Steiner M; Miles J; O'Brien T; McWilliams D; Schofield T; O'Reilly J; Hughes R Health Technol Assess; 2018 Mar; 22(11):1-204. PubMed ID: 29516853 [TBL] [Abstract][Full Text] [Related]
32. Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. Heaney LG; Busby J; Hanratty CE; Djukanovic R; Woodcock A; Walker SM; Hardman TC; Arron JR; Choy DF; Bradding P; Brightling CE; Chaudhuri R; Cowan DC; Mansur AH; Fowler SJ; Niven RM; Howarth PH; Lordan JL; Menzies-Gow A; Harrison TW; Robinson DS; Holweg CTJ; Matthews JG; Pavord ID; Lancet Respir Med; 2021 Jan; 9(1):57-68. PubMed ID: 32916135 [TBL] [Abstract][Full Text] [Related]
33. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study. Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796 [TBL] [Abstract][Full Text] [Related]
34. Effect of Vitamin D3 Supplementation on Severe Asthma Exacerbations in Children With Asthma and Low Vitamin D Levels: The VDKA Randomized Clinical Trial. Forno E; Bacharier LB; Phipatanakul W; Guilbert TW; Cabana MD; Ross K; Covar R; Gern JE; Rosser FJ; Blatter J; Durrani S; Han YY; Wisniewski SR; Celedón JC JAMA; 2020 Aug; 324(8):752-760. PubMed ID: 32840597 [TBL] [Abstract][Full Text] [Related]
35. An extended stroke rehabilitation service for people who have had a stroke: the EXTRAS RCT. Shaw L; Bhattarai N; Cant R; Drummond A; Ford GA; Forster A; Francis R; Hills K; Howel D; Laverty AM; McKevitt C; McMeekin P; Price C; Stamp E; Stevens E; Vale L; Rodgers H Health Technol Assess; 2020 May; 24(24):1-202. PubMed ID: 32468989 [TBL] [Abstract][Full Text] [Related]
36. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial. Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502 [TBL] [Abstract][Full Text] [Related]
37. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial. Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289 [TBL] [Abstract][Full Text] [Related]